Colorectal adenocarcinoma
MONDO:0005008The most common type of colorectal carcinoma. It is characterized by the presence of malignant glandular epithelial cells invading through the muscularis mucosa into the submucosa. Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.
Also known as: adenocarcinoma of large bowel, adenocarcinoma of large intestine, adenocarcinoma of the large bowel, adenocarcinoma of the large intestine, colorectal (colon or rectal) adenocarcinoma, colorectal adenocarcinoma, colorectum adenocarcinoma, large bowel adenocarcinoma
3425 clinical trials for this condition and its sub-types, 247 tagged with Colorectal adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Colorectal adenocarcinoma
-
Rectum adenocarcinoma 232 trials · 233 incl. sub-types
4 sub-types
- Anus adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectal signet ring cell adenocarcinoma 1 trial
- Rectum mucinous adenocarcinoma 1 trial Sub-types →
- Rectal medullary carcinoma 0 trials
-
Colon adenocarcinoma 90 trials · 121 incl. sub-types
5 sub-types
- Cecum adenocarcinoma 0 trials · 31 incl. sub-types Sub-types →
- Colon mucinous adenocarcinoma 2 trials · 21 incl. sub-types Sub-types →
- Colon signet ring cell adenocarcinoma 2 trials
- Colon medullary carcinoma 0 trials
- Submucosal invasive colon adenocarcinoma 0 trials
-
Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types
2 sub-types
-
Colorectal medullary carcinoma 0 trials
2 sub-types
- Colon medullary carcinoma 0 trials
- Rectal medullary carcinoma 0 trials
Most studied deeper sub-types
-
Can a Triple-Drug cocktail outsmart Treatment-Resistant colorectal cancer?
Disease control Stopped earlyThis phase 2 trial is testing whether adding an experimental drug called evorpacept to two existing cancer drugs (cetuximab and pembrolizumab) can shrink tumors in people with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study enro…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New immunotherapy combo aims to extend life in Tough-to-Treat colorectal cancer
Disease control Stopped earlyThis Phase 3 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can help people with advanced colorectal cancer that can't be removed by surgery and has stopped responding to chemotherapy. About 834 participants will receive either th…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Diet and drug combo aim to tame tumor side effects
Disease control Stopped earlyThis study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…
Phase 1 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Nutritional drink aims to cut surgery complications in colorectal cancer
Disease control Stopped earlyThis study tested whether a nutritional drink called Impact Oral®, taken for 5 days before and after surgery, could reduce complications in colorectal cancer patients. The trial included 71 patients eligible for minimally invasive surgery. However, the study was terminated early,…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising liver cancer combo trial halted early – only 4 patients enrolled
Disease control Stopped earlyThis phase 2 study tested a two-step treatment for colorectal cancer that had spread only to the liver and could not be removed by surgery. First, patients received radioactive beads (Holmium-166 TARE) directly into the liver, followed by maintenance chemotherapy and targeted dru…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental cancer drug ASP2074 trial halted early
Disease control Stopped earlyThis early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Cancer combo trial halted early: what we know
Disease control Stopped earlyThis phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…
Phase 2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo for colorectal cancer shows promise but trial halted early
Disease control Stopped earlyThis phase 2 trial tested a new drug combination (NUFIRI-bev) against the standard treatment (FOLFIRI-bev) in 171 people with metastatic colorectal cancer that had already been treated. The goal was to see if the new combo could delay cancer growth better than the standard. Howev…
Phase 2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jun 26, 2026 15:54 UTC
-
Glowing dye could help doctors see hidden tumors
Diagnosis Stopped earlyThis early study tested a special dye called VGT-309 that makes cancer cells glow during a colonoscopy. The goal was to see if it is safe and helps doctors find colorectal tumors more easily. The study was stopped early and included 9 adults with colorectal cancer.
Early phase 1 • Sponsor: Stephan Rogalla • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC